Investigating ways to inhibit the KRAS oncogene in cancer treatment

Cellular mechanisms and therapeutic possibilities of inhibiting oncogenic KRAS

NIH-funded research Hunter College · NIH-10686125

This study is looking at new ways to block a gene called KRAS that often causes cancer, with the hope of finding better treatments for patients with KRAS-related tumors.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionHunter College NIH-funded
Lab location1 site (New York, United States)
Project IDNIH-10686125 on NIH RePORTER

What this research studies

This research focuses on understanding how to inhibit the KRAS oncogene, which is frequently mutated in various cancers. The team is exploring new pharmacological agents that can bind to KRAS and prevent its harmful effects, potentially leading to cancer regression. By studying the cellular consequences of KRAS loss and the mechanisms behind these inhibitors, the research aims to identify effective combination therapies for patients with KRAS-driven tumors. This work could provide insights into targeted treatments for some of the most challenging cancers.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients with cancers that have mutations in the KRAS gene.

Not a fit: Patients with cancers not driven by KRAS mutations may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new therapies that effectively treat cancers driven by KRAS mutations.

How similar studies have performed: Other research has shown promise in targeting KRAS mutations, but this specific approach is novel and untested.

Where this research is happening

New York, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Anti-Cancer AgentsCancer DrugNeoplastic Disease Chemotherapeutic Agentsanti-cancer druganticancer agent
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.